Comparative Pharmacology
Head-to-head clinical analysis: PIROXICAM versus TOLECTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIROXICAM versus TOLECTIN.
PIROXICAM vs TOLECTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
10-20 mg orally once daily; maximum 20 mg/day.
400-600 mg orally three times daily; maximum 1.8 g/day.
None Documented
None Documented
Terminal elimination half-life is 50 hours (range 30-86 hours), allowing once-daily dosing. Prolonged in elderly (up to 80 hours) and in hepatic impairment.
Clinical Note
moderatePiroxicam + Gatifloxacin
"Piroxicam may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePiroxicam + Rosoxacin
"Piroxicam may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePiroxicam + Levofloxacin
"Piroxicam may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePiroxicam + Trovafloxacin
"Piroxicam may increase the neuroexcitatory activities of Trovafloxacin."
Terminal half-life approximately 5-6 hours; clinical context: dosing every 6-8 hours required due to relatively short half-life; steady-state achieved within 24-30 hours.
Approximately 60-70% renal (glomerular filtration and tubular secretion) as unchanged drug and metabolites; 30-40% fecal via biliary excretion. Less than 5% as unchanged drug in urine.
Renal (90-95% as unchanged drug and metabolites, primarily glucuronide conjugates); biliary/fecal (minor, <5%).
Category D/X
Category C
NSAID
NSAID